Who
Michael Aaron Kelly
Director
Company insider
Files Form 4 as: Director, Prime Medicine; Director, NeoGenomics; Director, DMC Global; Director, Amicus Therapeutics; Director, HOOKIPA Pharma; Director, Aprea Therapeutics.
In numbers
- Trades disclosed
- 80
- Buys
- 1
- Sells
- 0
- Bought
- $38K
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 17 Apr 2019
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | NEO NeoGenomicsProfessional Services | SEC FORM 4 Code M | —23,077 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code M | —23,077 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —11,069 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code M | —23,077 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —11,069 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —15,970 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | NEO NeoGenomicsoption or derivative · Professional Services | SEC FORM 4 Code A | —15,970 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | NEO NeoGenomicsProfessional Services | SEC FORM 4 Code M | —23,077 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | BOOM DMC GlobalSteel & Metals Processing | SEC FORM 4 Code A | —16,937 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | BOOM DMC GlobalSteel & Metals Processing | SEC FORM 4 Code A | —16,937 at $0.00 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus TherapeuticsBiotechnology | SEC FORM 4 Code D | $1.1M72,468 at $14.50 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —36,111 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,423 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —36,111 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —45,423 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,474 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —42,467 | filing |
| 27 Apr 2026filed 27 Apr 2026 | Amicus Therapeuticsoption or derivative | SEC FORM 4 Code D | —74,872 | filing |
News
NeoGenomics, Inc. (NASDAQ:NEO) Stock Has Average Target Price of $17.67NEO · tickerreport.com · 9 Oct 2026
0 headlines in the last 90 days name Michael Aaron Kelly; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.